Skip to main content
HR 3966 107th Congress House Science, Technology, Communications Capital investments Commercialization Congress Congressional reporting requirements Data banks Federal advisory bodies Finance and Financial Sector Gene therapy Genetic research Government Operations and Politics Health Human genetics Intellectual property Legislation Medical tests Patents Policy sciences Regulatory impact statements Research and development

Genomic Science and Technology Innovation Act of 2002

Introduced: March 14, 2002 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 107th Congress ended
It never became law before the 107th Congress (2001–2002) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 6, 2002
Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Mar 22, 2002
Referred to the Subcommittee on Research.
Mar 22, 2002
Referred to the Subcommittee on Environment, Technology, and Standards.
Mar 14, 2002
Referred to the Committee on Science, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 14, 2002
Sponsor introductory remarks on measure. (CR E353-355)
Mar 14, 2002
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Genomic Science and Technology Innovation Act of 2002 - Requires the Director of the Office of Science and Technology Policy to conduct, or contract with the National Academy of Sciences to conduct, a study that assesses the impact of Federal policies, including intellectual property policies, on the innovation process for genomic technologies.

Requires such study to: (1) identify and quantify the effects of innovation policy on genomic science and technology innovation; (2) consider alternative levels of intellectual property protection genomic materials may receive and the likely impact on each element of the innovation pipeline; and (3) assess the net impact of Federal innovative policies.

What's happening now May 6, 2002

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 5
 Cosponsors 1
All 1 Republican 1
R
Smith, Christopher H.
New Jersey · May 9, 2002
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3966: Genomic Science and Technology Innovation Act of 2002. 107th Congress. Open America. https://openamerica.io/bill/107-HR-3966/
MLA
"H.R. 3966: Genomic Science and Technology Innovation Act of 2002." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-HR-3966/.
Bluebook (legal)
H.R. 3966, 107th Cong. (2026), https://openamerica.io/bill/107-HR-3966/.
Markdown link
[H.R. 3966: Genomic Science and Technology Innovation Act of 2002](https://openamerica.io/bill/107-HR-3966/)
Report a problem